Funded Startups in Solna
Among the 6 most recent rounds tied to Solna, the largest disclosed amount is Moleculent’s $26M (2024-06-11).
Among the 6 most recent rounds tied to Solna, the largest disclosed amount is Moleculent’s $26M (2024-06-11). The next-largest disclosed rounds are Chromafora’s $24M (2024-12-20) and Ovzon’s $19M (2023-02-03), so Moleculent’s $26M is only modestly above the rest rather than a clear outlier. Amounts cluster in the mid-teens to mid-$20M range when disclosed, with Cellcolabs at $12M (2025-10-29) lowering the floor.
Rounds span 2023-02-03 (Ovzon) through 2025-10-29 (Cellcolabs), with multiple Biotechnology entries centered in Solna/Stockholms Lan in 2023–2024 (Pelago Bioscience 2023-08-16, lynes 2023-03-15, Moleculent 2024-06-11). Biotechnology appears in 3 of 6 rows, while 4 of 6 rows are labeled “Series Unknown” and 2 are “undisclosed” on amount. The list also shows a sector mix that is more concentrated in Biotechnology than Hardware or Telecommunications.
Most recent rounds
6 shownRelated listings
Frequently asked
What’s the largest disclosed round in this Solna set, and is it an outlier versus the rest?
Moleculent’s $26M (2024-06-11) is the largest disclosed amount. The next-largest disclosed rounds are Chromafora at $24M (2024-12-20) and Ovzon at $19M (2023-02-03), which keeps Moleculent from looking dramatically above the group.
Do these Solna rounds cluster in time, or are they spread out across different periods?
The 6 rows span 2023-02-03 (Ovzon) to 2025-10-29 (Cellcolabs). Within that window, 3 rounds fall in 2023 alone (Ovzon 2023-02-03, lynes 2023-03-15, Pelago Bioscience 2023-08-16), and 2 more appear in mid-to-late 2024 (Moleculent 2024-06-11 and Chromafora 2024-12-20).
Are any sectors over-represented among the six entries?
Biotechnology is over-represented at 3 of 6 rows (Cellcolabs 2025-10-29, Moleculent 2024-06-11, Pelago Bioscience 2023-08-16). Hardware (Ovzon, 2023-02-03) and Telecommunications (lynes, 2023-03-15) each appear once.
How much of the list lacks disclosed amounts or stage detail?
Half the entries show “Series Unknown” (Cellcolabs 2025-10-29, Chromafora 2024-12-20, Pelago Bioscience 2023-08-16, lynes 2023-03-15). In terms of amounts, two entries have “undisclosed” amounts (Pelago Bioscience 2023-08-16 and lynes 2023-03-15), leaving only four with dollar amounts for size comparisons.
Which entry could be the biggest sales lead based on disclosed round size, and what’s the next step down?
For disclosed amounts, Cellcolabs’ $12M (2025-10-29) and Ovzon’s $19M (2023-02-03) define the lower portion, while Moleculent’s $26M (2024-06-11) is the top. The next step down after Moleculent is Chromafora at $24M (2024-12-20), followed by Ovzon at $19M.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.